Preferences for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.

Completed

• Conditions: Cancer

• Registration Number: NCT05936632
• Lead Sponsor: London School of Economics and Political Science

Brief Summary

To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients.

It is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit.

This study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs.

To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-06-26
• Study First Submitted QC: 2023-07-04
• Study Start: 2023-07-07
• Study First Posted: 2023-07-10
• Primary Completion: 2023-07-20
• Study Completion: 2023-07-20
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-10
• Last Update Posted: 2024-06-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 998

Inclusion Criteria

• Individuals previously or currently diagnosed with any type of cancer.
• Individuals with immediate family members previously or currently diagnosed with any type of cancer.

Exclusion Criteria

• Individuals without previous or current diagnosis with any type of cancer (themselves or immediate family members).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Preferences for treatment attributes and trade-offs between attributes.	Through study completion, an average of 4-8 weeks.	Preferences for different treatment attributes (including clinical uncertainty and wait time), and trade-offs between these, using a study-specific Discrete Choice Experiment (DCE) Questionnaire. Preferences are measured on relative utility scale (arbitrary units, no min/max). Utility indicates preference e.g., higher values are more preferred (better).

Trial Locations

Locations (1)

London School of Economics; 🇬🇧 London, United Kingdom